SCHEMBL19974847

SCHEMBL19974847

CC(NC(=O)c1c(Cl)cccc1Cl)C(=O)C(=O)NCC1CC1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 5/20 0.44
POLB P06746 1/20 0.42
FBP1 P09467 1/20 0.42
CHRM1 P11229 2/20 0.42
CNR2 P34972 2/20 0.41
CNR1 P21554 1/20 0.41
TAS1R3 Q7RTX0 2/20 0.40
TAS1R1 Q7RTX1 2/20 0.40
TAS1R2 Q8TE23 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
DPP4 P27487 1/20 0.39
PREP P48147 1/20 0.39
FAP Q12884 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
SLC6A9 P48067 1/20 0.39
ITGB1 P05556 1/20 0.38
ITGA5 P08648 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19974903 0.90 ITGB1 (0.40) P2RX7POLBFBP1CHRM1CNR2
SCHEMBL19974873 0.86 SMN1; SMN2 (0.48) P2RX7CHRM1CNR2CNR1NPC1
SCHEMBL19975568 0.82 KCNH2 (0.51) POLBFBP1NPC1RAB9AHPGD
SCHEMBL21183565 0.81 RAB9A (0.47) P2RX7POLBNPC1RAB9AALDH1A1
SCHEMBL21176278 0.81 PREP (0.47) RAB9APREPFAPALDH1A1HPGD
SCHEMBL21183512 0.79 P2RX7 (0.43) P2RX7POLBFBP1CHRM1CNR2
SCHEMBL19975288 0.78 ATM (0.53) TAS1R3TAS1R1NPC1RAB9AHPGD
SCHEMBL19974989 0.78 MAPK14 (0.43) P2RX7NPC1RAB9AHPGD
SCHEMBL19974990 0.78 MAPK14 (0.43) P2RX7NPC1RAB9AHPGD
SCHEMBL19975398 0.78 MAPK14 (0.43) P2RX7NPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C P2RX7 339/4885POLB 833/4885FBP1 1520/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C P2RX7 564/4885POLB 617/4885FBP1 1154/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C P2RX7 339/4885POLB 833/4885FBP1 1520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.